A Canadian medical cannabis company has announced the launch of a high-potency cannabidiol (CBD) oil for patients.
Napanee, Ontario-based VIVO Cannabis Inc. on Tuesday announced the launch of the CBD+|O oil under its Beacon Medical brand.
According to VIVO CBD+|O oil is a 2:100 (THC:CBD) distillate-based cannabis oil with 100mg CBD and less than 2mg delta-9 tetrahydrocannabinol (THC).
VIVO says that Beacon Medical formulates all of its cannabis oil products using a non-GMO, food-grade medium-chain triglyceride (MCT) carrier oil.
According to VIVO, the carrier oil results in a final product that is scentless and flavorless.
VIVO CEO Ray Laflamme says that the company aspires to deliver premium cannabinoid-based medical products to patients through its commitment to the medical cannabis market.
“We recognize that many of our patients are looking for products that meet their individualized needs,” says Laflamme. “And this latest addition to the Beacon Medical family of products is an excellent high potency CBD option for patients, and it will be available to patients, doctors, and hospitals alike.”
Laflamme says that the launch of Beacon Medical CBD+|O is in response to patient insights that the company team has collected over time.
VIVO has also launched the Pediatric Compassionate Care Program to support families and caregivers who require cannabis to treat various medical conditions.
According to VIVO, eligible patients will receive substantial discounts on all CBD products from Beacon Medical, Canna Farms, Fireside, and Lumina.
VIVO says it stands strong on its patient-first approach to guarantee access, choice, and a consistent supply for medical cannabis patients in Canada, Australia, and Germany.
The new Beacon Medical CBD+|O high-potency oil is available via the Canna Farms e-commerce medical marketplace for patients in Canada.